ICUI · ICU Medical, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on ICUI. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About ICUI · ICU Medical, Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Live Quote
HOLD (score +1) · 12-1 mom 0.3% · RSI 50.4 · above_both · -14.5% from high
Targets blend Wall Street consensus (8 analysts: low $160.00 / mean $172.50 / high $200.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Score of 29/100 reflects a complete absence of insider buying, elevated leverage (~3.4x net debt/EBITDA), and an unresolved FDA warning letter that outweigh the modest valuation discount. Anti-signal flags for dilution and concentration, combined with a score well below the skip threshold, justify passing on this dossier.
Score of 29/100 reflects a complete absence of insider buying, elevated leverage (~3.4x net debt/EBITDA), and an unresolved FDA warning letter that outweigh the modest valuation discount. Anti-signal flags for dilution and concentration, combined with a score well below the skip threshold, justify passing on this dossier.
ICU Medical is a pure-play infusion therapy and vascular access medical device company that has undergone significant structural transformation — the divestiture of the IV Solutions business to an Otsuka JV in May 2025 explains most of the reported -12% revenue decline. Forward P/E of ~13x with analyst targets near $174 represents meaningful upside, but no true open-market insider purchases were found: the recent Form 4 cluster consists entirely of RSU vesting with simultaneous tax-withholding sales (F-codes) and option exercises converted at market prices. No director or executive bought ICUI on the open market in the past 90 days. The stock is near its 52-week low, below both moving averages but has a recent MACD bullish cross, giving it income/strangle potential rather than an asymmetric long setup.